000			02242 a2200613 4500
005			20250516003611.0
264		0	_c20110819
008			201108s 0 0 eng d
022			_a1097-685X
024	7		_a10.1016/j.jtcvs.2010.08.035 _2doi
040			_aNLM _beng _cNLM
100	1		_aSmith, Peter K
245	0	0	_aEffects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. _h[electronic resource]
260			_bThe Journal of thoracic and cardiovascular surgery _cJul 2011
300			_a89-98 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAnti-Inflammatory Agents _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aCardiopulmonary Bypass
650	0	4	_aChi-Square Distribution
650	0	4	_aComplement C5 _xantagonists & inhibitors
650	0	4	_aCoronary Artery Bypass _xadverse effects
650	0	4	_aCoronary Artery Disease _ximmunology
650	0	4	_aDouble-Blind Method
650	0	4	_aEurope
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInfusions, Intravenous
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMyocardial Infarction _ximmunology
650	0	4	_aNorth America
650	0	4	_aProportional Hazards Models
650	0	4	_aRisk Assessment
650	0	4	_aRisk Factors
650	0	4	_aSingle-Chain Antibodies _xadministration & dosage
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
700	1		_aShernan, Stanton K
700	1		_aChen, John C
700	1		_aCarrier, Michel
700	1		_aVerrier, Edward D
700	1		_aAdams, Peter X
700	1		_aTodaro, Thomas G
700	1		_aMuhlbaier, Lawrence H
700	1		_aLevy, Jerrold H
773	0		_tThe Journal of thoracic and cardiovascular surgery _gvol. 142 _gno. 1 _gp. 89-98
856	4	0	_uhttps://doi.org/10.1016/j.jtcvs.2010.08.035 _zAvailable from publisher's website
999			_c20208974 _d20208974